Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia

Abstract

Introduction: Today, recommendations about initial Response Evaluation Criteria in Solid Tumor (RECIST) and its frequency still vary, while early diagnosis of progression affects patient’s prognosis and subsequent treatment options.

Keywords

• adenocarcinoma
• egfr
• neutrophil-to-lymphocyte ratio
• tyrosine kinase inhibitor
• progression free survival